ASH News Daily 2012 - Sunday, December 9, 2012 - (Page B-11)

Sunday, December 9, 2012 ASH NewS DAily Page B–11 ® Public Service, Outstanding Service Awards to be Presented Today Senator Klobuchar, Congressional Leader of Efforts to Combat Drug Shortages, Honored With 2012 Public Service Award Public Service. Sen. Klobuchar, who was first elected to the U.S. Senate in 2006 and is currently serving her first term representing the state of Minnesota, was the first person in Congress to bring to light the problem of prescription drug shortages and introduced the Preserving Access to Life-Saving Medications Act (S. 296) in February 2011. Her bill, which became the foundation for all further legislative efforts and for legislation ultimately passed as part of the Prescription Drug User Fee Act, addressed the critical shortages of certain hematology-related chemotherapy and other lifesaving drugs by requiring prescription drug manufacturers to give early notification to the Food and Drug Administration of any incident that would likely result in a drug shortage. The Society applauds Sen. Klobuchar’s leadership to combat the critical shortages of drugs used to treat cancer and other serious ailments. Without her efforts, this legislative priority would not have moved forward. Sen. Klobuchar was re-elected for another term representing Minnesota. »» AWARDS Page B-12 Senator Amy Klobuchar (D-MN) E stablished in 1997, the Public Service Award is presented each year by ASH to an elected public official who has demonstrated unparalleled leadership on issues of importance to hematology research and/or practice. This year, the Society will honor Senator Amy Klobuchar with the ASH Award for After multiple failures, Visit us at booth #2533 single-agent response Indicated for the treatment of: • Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT)1 • HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens1 Important Safety Information (continued) • Progressive multifocal leukoencephalopathy (PML): JC virus infection resulting in PML and death has been reported in ADCETRIS™ (brentuximab vedotin)– treated patients. In addition to ADCETRIS therapy, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression. Consider the diagnosis of PML in any patient presenting with newonset signs and symptoms of central nervous system abnormalities. Evaluation of PML includes, but is not limited to, consultation with a neurologist, brain MRI, and lumbar puncture or brain biopsy. Hold ADCETRIS if PML is suspected and discontinue ADCETRIS if PML is confirmed. • Stevens-Johnson syndrome: Stevens-Johnson syndrome has been reported with ADCETRIS. If Stevens-Johnson syndrome occurs, discontinue ADCETRIS and administer appropriate medical therapy. • Use in pregnancy: Fetal harm can occur. Pregnant women should be advised of the potential hazard to the fetus. ADCETRIS was studied as monotherapy in 160 patients in two phase 2 trials. Across both trials, the most common adverse reactions (≥20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough and vomiting. Patients who are receiving strong CYP3A4 inhibitors concomitantly with ADCETRIS should be closely monitored for adverse reactions. HL: 73% objective response rate (ORR) (95% CI: 65%-83%) 32% complete remission (95% CI: 23%-42%)1 1 40% partial remission (95% CI: 32%-49%)1 N = 102 15 77 years (median: 31 years)1 102, 15-77 (median: 3 an: a • Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen1 sALCL: 86% ORR (95% CI: 77%-95%) 57% complete remission (95% CI: 44%-70%)1 N = 58 14 76 years (median 52 years)1 58, 14-76 (median: 1 29% partial remission (95% CI: 18%-41%)1 The indications for ADCETRIS™ (brentuximab vedotin) are based on response rate. There are no data available demonstrating improvement in patient-reported outcomes or survival with ADCETRIS.1 Adverse Reactions: 2011 August 19 Acq Tm: 14:05:52 512x512 B Drug Interactions: A R Vp L Please see Brief Summary of full Prescribing Information, including Boxed WARNING, on the last page of this ad. REFERENCE: 1. ADCETRIS [Prescribing Information]. Bothell, WA: Seattle Genetics, Inc; 2012. US/BVP/2011/0104h 855.4SEAGEN (855.473.2436) SeaGenSecure.com 2860_sgn35_fa1_jog_ashnd.indd 2 10/15/12 5:28 PM 

Table of Contents for the Digital Edition of ASH News Daily 2012 - Sunday, December 9, 2012

ASH News Daily 2012 - Sunday, December 9, 2012

https://www.nxtbookmedia.com